Atlas Molecular Pharma will be attending BIO-Europe Spring 2026, starting March 23. CEO Susana Castel and Business Development Manager Luis Ruiz-Avila will participate in the event as we continue advancing partnering discussions around ATL-001, our lead clinical program for Congenital Erythropoietic Porphyria (CEP), an ultra-rare and severe metabolic disorder with no approved therapies. We are encouraged by the strong interest received in recent months and look forward to continuing conversations with partners and stakeholders in the rare disease and specialty pharma space during the meeting.
